Exact Sciences Corporation
Could not find a ticker for this position, may be a filing error
A diagnostics company focused on early cancer screening, Exact Sciences makes Cologuard—a stool-based test people collect at home to spot colorectal cancer, a noninvasive alternative to a colonoscopy. Founded in 1995 in Massachusetts by Stanley Lapidus and Anthony Shuber, it built Cologuard alongside the Mayo Clinic, and the FDA cleared the test in 2014. The name blends "colo" for colon and "guard," underscoring the test's protective role.
1% Convertible Senior Notes due 15-Jan-2025
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 26, 2026 |
| Capital World Investors | 13G/APassive | 0.5% | 968.2K | Feb 13, 2026 |
| FMR LLC | 13G/APassive | 2.9% | 5.51M | Dec 5, 2025 |
| Abigail P. Johnson | 13G/APassive | 2.9% | 5.51M | Dec 5, 2025 |
| Wellington Management Group LLP | 13G/APassive | 3% | 5.75M | Nov 12, 2025 |
| Wellington Group Holdings LLP | 13G/APassive | 3% | 5.75M | Nov 12, 2025 |
| Wellington Investment Advisors Holdings LLP | 13G/APassive | 3% | 5.75M | Nov 12, 2025 |
| BlackRock, Inc. | 13G/APassive | 4.3% | 8.07M | Jul 17, 2025 |